David Sinclair Longevity Protocol: What It Would Cost a Non-Celebrity

Who Is David Sinclair and Why Does His Protocol Matter?

David Sinclair is a Professor of Genetics at Harvard Medical School, co-director of the Paul F. Glenn Center for Biology of Aging Research, and author of the 2019 book "Lifespan: Why We Age and Why We Don't Have To." His work centers on NAD+ metabolism, sirtuin activation, and the information theory of aging. Because he publishes his own regimen openly on podcasts and social media, his stack has become a reference point for the broader longevity community.

His visibility matters clinically. Patients arrive at telehealth platforms and physicians' offices asking specifically for "what Sinclair takes." That makes a clear, evidence-graded breakdown medically necessary, not merely interesting.

Sinclair's Self-Reported Regimen

Sinclair has described his daily stack in multiple public forums, including a 2023 appearance on the Huberman Lab podcast and his own "Lifespan" podcast. His reported routine includes:

• NMN (nicotinamide mononucleotide): 1 gram each morning
• Resveratrol: 1 gram each morning, taken with a small amount of fat (typically Greek yogurt) to improve absorption
• Metformin: 1 gram at night (he has noted he skips it before intense exercise)
• Vitamin D3: 4,000 to 5,000 IU daily
• Vitamin K2: 180 mcg daily
• Low-dose aspirin: 83 mg daily
• Rapamycin: periodic, lower-dose pulsed dosing (exact schedule varies by interview)
• Spermidine: added more recently in some interviews
• Alpha-lipoic acid and coenzyme Q10: mentioned historically, less recently

He has also publicly stated he monitors biological age using epigenetic clocks (such as the Horvath clock) and tracks standard labs including glucose, insulin, lipids, and CRP.

What Sinclair Has Actually Said (Verbatim)

In a 2022 episode of the Lex Fridman Podcast, Sinclair stated: "I take NMN every morning with a gram of resveratrol. I take metformin at night, a gram. I don't take it before I exercise because there's some evidence that metformin blunts the benefits of exercise." This is a direct self-report, not a clinical recommendation.

The HealthRX medical team's evidence-grading framework below separates Sinclair's self-reported anecdote from peer-reviewed data. Each compound is graded A (strong RCT evidence), B (moderate or indirect evidence), or C (animal/in-vitro/preliminary human data only).

Metformin: The Strongest Evidence in the Stack

Metformin is a biguanide approved by the FDA since 1994 for Type 2 diabetes management [1]. At 500 to 2,000 mg/day, it reduces hepatic glucose output and activates AMPK, a pathway associated with cellular energy sensing and autophagy.

What the Clinical Data Show

The UKPDS 34 trial (N=1,704) demonstrated that metformin reduced all-cause mortality by 36% and myocardial infarction risk by 39% in overweight patients with newly diagnosed Type 2 diabetes compared to conventional treatment (P<0.001) [2]. This is diabetes data, not longevity data.

The Targeting Aging with Metformin (TAME) trial, a landmark NIH-funded study led by Nir Barzilai at Albert Einstein College of Medicine, is testing whether 1,500 mg/day of metformin can delay the composite onset of age-related diseases in non-diabetic adults aged 65 to 79. Results are expected after 2025 [3]. Until TAME reports, metformin's longevity benefit in non-diabetics remains unproven in a prospective RCT.

Cost Without Insurance

Generic metformin ER 500 mg costs approximately $10, $18 per month at GoodRx prices at major US pharmacies for a 1,000 mg/day dose. A prescription is required. For patients without diabetes, many physicians will prescribe off-label; some will not. Cash-pay telehealth platforms typically charge $30, $75 per month including the prescription and monitoring visit.

Key Safety Consideration

Metformin is contraindicated in patients with an eGFR <30 mL/min/1.73 m² and should be used with caution when eGFR is <45 [4]. Lactic acidosis is rare but serious. Vitamin B12 levels should be checked annually with long-term use, as metformin reduces B12 absorption in approximately 7% of chronic users [5].

NMN: Promising but Still Early

NMN is a direct precursor to NAD+. Sinclair's NAD+ research, along with work by Charles Brenner and others, has established that NAD+ levels decline with age in multiple tissues [6]. Restoring NAD+ in preclinical models extends lifespan and improves metabolic function in rodents.

Human Trial Data

A 12-week double-blind RCT published in npj Aging and Mechanisms of Disease (N=25 healthy adults, ages 45 to 60) found that oral NMN 250 mg/day significantly increased whole-blood NAD+ levels vs. Placebo (P<0.001) [7]. A separate trial by Yoshino et al. Published in Science (N=25 postmenopausal women with prediabetes, 2021) showed NMN 250 mg/day improved skeletal muscle insulin sensitivity compared to placebo [8]. Neither trial measured mortality, biological age, or long-term disease outcomes.

Cost Reality

NMN 1 g/day (Sinclair's dose) from reputable suppliers costs $80, $180 per month. Quality control is a real concern. NMN is sold as a supplement in the US, meaning it bypasses FDA manufacturing oversight that applies to prescription drugs. Third-party tested brands from NSF or USP-certified facilities cost more.

A 2021 FDA notice raised the question of whether NMN qualifies as a drug rather than a dietary supplement, given prior IND filings. As of early 2025, the legal status remains unsettled [9].

Resveratrol: A Sirtuin Activator With Complicated Human Data

Resveratrol is a polyphenol found in red wine and grape skins. Sinclair's lab published foundational work in Nature (2003) showing resveratrol activated SIRT1 in yeast and extended yeast lifespan [10]. This generated enormous scientific excitement.

Where the Evidence Stands Today

Human trial results have been mixed. A randomized trial by Bhatt et al. (N=119, 2012) published in Cell Metabolism found that resveratrol 150 mg/day improved metabolic markers in obese men. However, a larger study by Poulsen et al. (N=24, published in Diabetes, 2013) found that resveratrol 1,500 mg/day had no significant effect on insulin sensitivity or metabolic endpoints in well-controlled Type 2 diabetic patients [11]. The Cochrane systematic review on resveratrol and cardiovascular outcomes (2018) concluded that evidence remains insufficient to support routine use [12].

Bioavailability is poor. Oral resveratrol is rapidly metabolized; plasma half-life is roughly 1 to 3 hours, which is why Sinclair emphasizes taking it with fat.

Cost

Resveratrol 1 g/day (as trans-resveratrol from a reputable supplier) costs approximately $40, $90 per month. It is available over the counter. Like NMN, supplement quality varies significantly across brands.

Rapamycin: The Most Controversial Item on the List

Rapamycin (sirolimus) is an mTOR inhibitor approved by the FDA for prevention of organ transplant rejection and treatment of certain cancers [13]. It is the most evidence-supported longevity compound in mammalian models.

Animal Evidence Is Unusually Strong

The Interventions Testing Program (ITP), funded by the National Institute on Aging, demonstrated that rapamycin extended median lifespan in genetically heterogeneous mice by 9 to 14% even when started at 20 months of age (roughly equivalent to a 60-year-old human) [14]. This is one of the most replicated findings in geroscience.

Human Data Remain Limited

No large prospective RCT has tested rapamycin for longevity endpoints in healthy humans. A small Phase 2 study (PEARL trial, N=228 healthy adults aged 50 to 85) is ongoing as of 2025 [15]. A 2018 study by Mannick et al. Published in Science Translational Medicine (N=264) tested the rapalog RTB101 and found improved immune function and reduced infection rates in older adults, offering indirect support [16].

Sinclair has mentioned taking rapamycin in periodic low doses rather than daily, a strategy some geroscientists favor to reduce immunosuppressive side effects. Standard transplant doses run 1 to 5 mg/day continuously; longevity-focused physicians often prescribe 3 to 6 mg once weekly off-label.

Cost and Access

Generic sirolimus 1 mg tablets cost approximately $150, $400 per month for weekly longevity dosing at cash-pay prices. A prescribing physician is required. The side-effect profile at higher or continuous doses includes impaired wound healing, hyperlipidemia, oral ulcers, and immune suppression. Monitoring lipid panels and CBC is standard practice [17].

Vitamin D3, K2, and Aspirin: Lower-Cost Foundations

These three items round out the reported Sinclair stack and are substantially cheaper.

Vitamin D3 and K2

The Endocrine Society guideline recommends vitamin D3 supplementation for adults with documented deficiency (serum 25-OH vitamin D <20 ng/mL) [18]. Sinclair takes 4,000 to 5,000 IU daily. At this dose, annual 25-OH vitamin D monitoring is prudent given the risk of hypercalcemia at sustained levels above 100 ng/mL.

Vitamin K2 (menaquinone-7) may reduce arterial calcification risk, though a 2022 systematic review in Nutrients concluded that evidence from large RCTs remains inconclusive [19]. Cost: D3 5,000 IU plus K2 180 mcg runs roughly $10, $20 per month combined.

Low-Dose Aspirin

The 2022 USPSTF guideline update recommended against initiating aspirin for primary cardiovascular prevention in adults aged 60 and older due to bleeding risk outweighing benefit in that group [20]. For adults aged 40 to 59 with a 10-year CVD risk of 10% or greater, the USPSTF gives a grade C recommendation (individual decision). Aspirin 81 mg costs approximately $3, $5 per month.

Total Cost Breakdown for a Non-Celebrity Patient

Most people do not have access to a Harvard genetics lab, private concierge physicians, or employer-funded research. Here is a realistic monthly cost estimate for a US adult attempting to replicate Sinclair's stack through legitimate channels:

| Component | Monthly Cost (US, cash-pay) | Prescription Required | |---|---|---| | Metformin 1,000 mg/day (generic) | $10, $18 (drug) + $30, $75 (telehealth Rx) | Yes | | NMN 1 g/day (third-party tested) | $80, $180 | No | | Resveratrol 1 g/day (trans-resveratrol) | $40, $90 | No | | Rapamycin 4 to 6 mg/week (generic sirolimus) | $150, $400 (drug) + $50, $100 (Rx + monitoring) | Yes | | Vitamin D3 5,000 IU + K2 180 mcg | $10, $20 | No | | Low-dose aspirin 81 mg/day | $3, $5 | No | | Epigenetic age testing (optional, annual) | $300, $500 (one-time, annualized $25, $42/month) | No | | Total (without rapamycin) | $173, $388/month | | | Total (with rapamycin) | $373, $913/month | |

These figures assume generic drugs and mid-tier supplement brands. Premium NMN brands or compounded formulations can push costs higher.

What a Clinician Would Actually Prescribe Today

Sinclair's stack sits at the intersection of evidence-based medicine and experimental geroscience. No major clinical guideline body, including the American College of Endocrinology or the Endocrine Society, currently recommends NMN, resveratrol, or rapamycin for healthy adults seeking longevity benefits [21].

A Reasonable Evidence-Tiered Approach

A clinician working with a motivated, healthy patient who wants the most defensible version of a longevity protocol might approach it this way:

Tier 1 (strong evidence, low risk): Vitamin D3 to correct documented deficiency. Metformin off-label if the patient is prediabetic (HbA1c 5.7 to 6.4%), given the American Diabetes Association's 2023 Standards of Care, which support metformin for diabetes prevention in high-risk adults [22]. Aspirin only if individual CVD risk justifies it per USPSTF 2022 guidance.

Tier 2 (moderate evidence, requires monitoring): NMN 250 to 500 mg/day as a well-tolerated NAD+ precursor with emerging human data. Annual labs to track metabolic markers.

Tier 3 (investigational, requires informed consent and specialist oversight): Rapamycin off-label with lipid monitoring, CBC, and a clear documented discussion of unknown long-term risk in healthy adults.

Monitoring Labs Sinclair Reports Tracking

Sinclair has publicly described monitoring the following at regular intervals: fasting glucose, insulin, HbA1c, lipid panel, CRP (high-sensitivity), complete blood count, liver function, vitamin D (25-OH), homocysteine, and epigenetic age. This level of monitoring costs $200, $600 per year in lab fees and is clinically appropriate for anyone on metformin or rapamycin.

Insurance Coverage: The Honest Answer

Almost none of this stack is covered by standard US health insurance for longevity indications.

Metformin is covered for Type 2 diabetes under most plans, including Medicare Part D. An off-label prescription for prediabetes or longevity prevention may or may not be covered depending on the plan and the diagnostic code used. NMN, resveratrol, spermidine, and most other supplements are not covered by any US insurance plan. Rapamycin is covered for transplant rejection and approved oncology indications; off-label longevity use is not covered.

HSA and FSA funds may be used for prescription drugs (metformin, rapamycin) and for eligible lab testing. Supplements are generally not HSA-eligible without a Letter of Medical Necessity, and even then, eligibility varies by plan administrator.

Risks of Replicating This Stack Without Medical Oversight

Metformin Without Monitoring

Patients with undiagnosed kidney disease who take metformin face a real risk of lactic acidosis. A baseline metabolic panel and periodic eGFR checks are not optional [4].

Rapamycin Without Specialist Involvement

Rapamycin at even low pulsed doses has measurable immunosuppressive effects. A patient who develops an infection while on rapamycin may have a blunted immune response. Wound healing after surgery or injury may be impaired. These risks are manageable with oversight; they are not manageable without it.

Supplement Quality

NMN and resveratrol are unregulated as dietary supplements. A 2020 study in the Journal of Dietary Supplements found that many NMN products delivered significantly less active ingredient than labeled [23]. Paying for NSF-certified or USP-verified products is a practical harm-reduction step.